A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date).

C Main; L Bojke; S Griffin; G Norman; M Barbieri; L Mather; D Stark; S Palmer; R Riemsma

A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date).

C Main, L Bojke, S Griffin, G Norman, M Barbieri, L Mather, D Stark, S Palmer, R Riemsma

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1-173
Number of pages	173
Journal	Health Technology Assessment
Volume	10(9):
Publication status	Published - 2006

Access to Document

http://www.hta.ac.uk/fullmono/mon1009.pdf

Cite this

Main, C., Bojke, L., Griffin, S., Norman, G., Barbieri, M., Mather, L., Stark, D., Palmer, S., & Riemsma, R. (2006). A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date). Health Technology Assessment, 10(9):, 1-173. http://www.hta.ac.uk/fullmono/mon1009.pdf

@article{1bc6edeea2fb43baa407779a6bdf08cf,

title = "A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date).",

author = "C Main and L Bojke and S Griffin and G Norman and M Barbieri and L Mather and D Stark and S Palmer and R Riemsma",

year = "2006",

language = "English",

volume = "10(9):",

pages = "1--173",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NHS National Institute for Health Research",

}

Main, C, Bojke, L , Griffin, S , Norman, G, Barbieri, M, Mather, L, Stark, D, Palmer, S & Riemsma, R 2006, 'A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date).', Health Technology Assessment, vol. 10(9):, pp. 1-173. <http://www.hta.ac.uk/fullmono/mon1009.pdf>

A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date). / Main, C; Bojke, L ; Griffin, S et al.
In: Health Technology Assessment, Vol. 10(9):, 2006, p. 1-173.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A systematic review of the clinical effectiveness and cost effectiveness of topotecan, pegylated liposomal doxorubicin hydrocholoride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (up-date).

AU - Main, C

AU - Bojke, L

AU - Griffin, S

AU - Norman, G

AU - Barbieri, M

AU - Mather, L

AU - Stark, D

AU - Palmer, S

AU - Riemsma, R

PY - 2006

Y1 - 2006

M3 - Article

SN - 2046-4924

VL - 10(9):

SP - 1

EP - 173

JO - Health Technology Assessment

JF - Health Technology Assessment

ER -